Molecular Modeling Studies of Natural Inhibitors of Androgen Signaling in Prostate Cancer

Molecular Modeling Studies of Natural Inhibitors of Androgen Signaling in Prostate Cancer

Prostate cancer is the second most common disease in men and the sixth leading cause of death from cancer globally, with 20 million men expected to be affected by 2024 thus considered as chronic illness which requires immediate attention. As an androgen-dependent illness that relies on the androgen...

Full description

Bibliographic Details
Main Authors:	Samuel O Olubode, Mutolib O Bankole, Precious A Akinnusi, Olayinka S Adanlawo, Kehinde I Ojubola, Daniel O Nwankwo, Onome E Edjebah, Ayomide O Adebesin, Abigail O Ayodele
Format:	Article
Language:	English
Published:	SAGE Publishing 2022-08-01
Series:	Cancer Informatics
Online Access:	https://doi.org/10.1177/11769351221118556

Similar Items

Computational study of the inhibitory potential of Gongronema latifolium (benth) leave on farnesyl pyrophosphate synthase, a target enzyme in the treatment of osteoporosis. A molecular modelling approach
by: Samuel O. Olubode, et al.
Published: (2022-08-01)

Computational evaluation of bioactive compounds from Vitis vinifera as a novel β-catenin inhibitor for cancer treatment
by: Ayomide Oluwadarasimi Adebesin, et al.
Published: (2022-06-01)

Discovery of Promising Inhibitors of Epidermal Growth Factor Receptor (EGFR), Human Epidermal Growth Factor Receptor 2 (HER2), Estrogen Receptor (ER), and Phosphatidylinositol-3-kinase a (PI3Ka) for Personalized Breast Cancer Treatment
by: Precious A Akinnusi, et al.
Published: (2022-10-01)

Structure-based scoring of anthocyanins and molecular modeling of PfLDH, PfDHODH, and PfDHFR reveal novel potential P. falciparum inhibitors
by: Precious A. Akinnusi, et al.
Published: (2023-01-01)

Comparison of nutritional composition, HPLC characterization, antioxidants property and starch profile of Sphenostylis stenocarpa composite bread and wheat bread
by: Sidiqat Adamson Shodehinde, et al.
Published: (2022-12-01)

Molecular binding studies of anthocyanins with multiple antiviral activities against SARS-CoV-2
by: Precious Ayorinde Akinnusi, et al.
Published: (2022-04-01)

A molecular modeling approach for structure-based virtual screening and identification of novel anti-hypercholesterolemic agents from Grape
by: Precious A. Akinnusi, et al.
Published: (2022-01-01)

ANTI-ANDROGENS IN TREATMENT OF PROSTATE-CANCER - REPLY
by: Dalesio, O, et al.
Published: (1995)

Potential Inhibitory Biomolecular Interactions of Natural Compounds With Different Molecular Targets of Diabetes
by: Precious A Akinnusi, et al.
Published: (2023-04-01)

Androgen blockade in prostate cancer - Authors' reply
by: Dalesio, O, et al.
Published: (2000)

Saponin-rich extracts reverse obesity and offer protection against obesity-induced inflammation in high-fat diet mice
by: Oluwamodupe C. Ejelonu, et al.
Published: (2021-01-01)

Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer
by: Mark N Stein, et al.
Published: (2014-06-01)

Regulation of ADAMTS expression in prostate cancer and stromal cells by androgen and TNF
by: Molokwu, C, et al.
Published: (2007)

Androgen regulates ADAMTS15 gene expression in prostate cancer cells.
by: Molokwu, C, et al.
Published: (2010)

Factors that influence the androgen receptor cistrome in benign and malignant prostate cells
by: Ben T. Copeland, et al.
Published: (2019-12-01)

Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells
by: Shtutman Michael, et al.
Published: (2010-04-01)

Assessment of androgen receptor signaling inhibitors therapy in metastatic hormone-sensitive prostate cancer
by: Jukapun Yoodee, et al.
Published: (2022-11-01)

The JNK inhibitor AS602801 Synergizes with Enzalutamide to Kill Prostate Cancer Cells In Vitro and In Vivo and Inhibit Androgen Receptor Expression
by: Zhenghong Li, et al.
Published: (2020-04-01)

Choosing Kinase Inhibitors for Androgen Deprivation Therapy-Resistant Prostate Cancer
by: Shangwei Zhong, et al.
Published: (2022-02-01)

Androgens and prostate disease
by: Lori A Cooper, et al.
Published: (2014-04-01)

LOWER URINARY TRACT SYMPTOMS CAUSED BY BENIGN PROSTATIC HYPERPLASIA: RESULTS OF TREATMENT DEPENDING ON ANDROGEN STATUS
by: O. I. Bratchikov, et al.
Published: (2018-05-01)

Development of an Androgen Receptor Inhibitor Targeting the N-Terminal Domain of Androgen Receptor for Treatment of Castration Resistant Prostate Cancer
by: Fuqiang Ban, et al.
Published: (2021-07-01)

The Risk of Venous Thromboembolism (VTE) in Men with Benign Prostatic Hyperplasia Treated with 5-Alpha Reductase Inhibitors (5ARIs).
by: Ayodele O, et al.
Published: (2021-08-01)

Effects of androgen receptor and androgen on gene expression in prostate stromal fibroblasts and paracrine signaling to prostate cancer cells.
by: Matthew J Tanner, et al.
Published: (2011-01-01)

TIMP-3 expression is regulated by androgen and TNF in prostate stromal and cancer cells
by: Adeniji, O, et al.
Published: (2008)

TIMP-3 expression in prostate stromal and tumour cells is regulated by androgen and TNF
by: Adeniji, O, et al.
Published: (2007)

Androgen Receptor Signaling Positively Regulates Monocytic Development
by: Camila Rosat Consiglio, et al.
Published: (2020-10-01)

Androgen receptor and prostate cancer
by: Karen E. Livermore, et al.
Published: (2016-06-01)

ANDROGEN DEFICIENCY AND PROGRESSION OF BENIGN PROSTATIC HYPERPLASIA IN PATIENTS WITH METABOLIC SYNDROME: IS THERE ANY CONTROVERSY? (A LITERATURE REVIEW)
by: V. I. Kirpatovskiy, et al.
Published: (2017-11-01)

Regulation of ADAMTS15 by dihydrotestosterone in prostate cancer cells and identification of putative androgen response elements
by: Molokwu, C, et al.
Published: (2009)

CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer
by: Justin H. Hwang, et al.
Published: (2019-11-01)

Modulating Androgen Receptor-Driven Transcription in Prostate Cancer with Selective CDK9 Inhibitors
Published: (2021)

Modulating Androgen Receptor-Driven Transcription in Prostate Cancer with Selective CDK9 Inhibitors
by: Richters, André, et al.
Published: (2022)

Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer
by: Rosenberg JE, et al.
Published: (2012-01-01)

Efficacy of different modes of pharmacotherapy for men with lower urinary tract symptoms benign prostatic hyperplasia depending of androgenic status
by: O. I. Bratchikov, et al.
Published: (2017-02-01)

Response to Androgens and Androgen Receptor Antagonists in the Presence of Cytokines in Prostate Cancer
by: Zoran Culig
Published: (2021-06-01)

Androgen Metabolism and Response in Prostate Cancer Anti-Androgen Therapy Resistance
by: Haozhe Zhang, et al.
Published: (2022-11-01)

The Androgen Receptor and VEGF: Mechanisms of Androgen-Regulated Angiogenesis in Prostate Cancer
by: Kurtis Eisermann, et al.
Published: (2017-04-01)

Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer
by: Lin Hui-Ping, et al.
Published: (2011-08-01)

Androgen receptor signaling is required for androgen-sensitive human prostate cancer cell proliferation and survival
by: Day Wanda V, et al.
Published: (2005-04-01)